{
    "title": "The Visceral Adiposity Index (VAI) and Lipid Accumulation Product (LAP) Are Predictors of Insulin Resistance and Hyperandrogenaemia in Obesity/Overweight Women with Polycystic Ovary Syndrome",
    "journal": "BioMed Research International",
    "publication_date": "2023",
    "abstract": "Hyperandrogenaemia and insulin resistance (IR) are the main characteristics of polycystic ovary syndrome (PCOS). Here, we study to find appropriate markers predicting IR and hyperandrogenaemia of women with PCOS in northwest China.   According to body mass index (BMI), 953 patients with PCOS were divided into two groups. All the patients underwent physical examination and ultrasonography and collected elbow vein blood. Their BMI, waist-to-height ratio (WHtR), waist-to-hip ratio (WHR), LAP, VAI, homeostasis model assessment index of insulin resistance (HOMA-IR), and free androgen index (FAI) were calculated. Each group (normal weight and obesity/overweight) was further divided into two subgroups according to their HOMA-IR and FAI: the IR+ subgroup/IR- subgroup and FAI+ subgroup/FAI- subgroup. Furthermore, we compared the clinical indices, hormone levels, and metabolic makers separately between these groups. The correlations between these parameters and HOMA-IR or FAI were tested; sensitivity, specificity, and receiver-operating characteristic (ROC) curves were calculated.   In the obesity/overweight group, the VAI (best cut-off value: 2.27, area\u2009under\u2009the\u2009curve\u2009(AUC) = 0.699) and LAP (best cut-off value: 45.54, AUC = 0.680) were sensitive predictors of IR (sensitivity = 72% and sensitivity = 67%). Additionally, the VAI (best cut-off value: 2.13, AUC = 0.624) and LAP (best cut-off value: 51.18, AUC = 0.582) were sensitive predictors of FAI (sensitivity = 87% and sensitivity = 64%). In the normal weight group, BMI could preferably predict HOMA-IR (AUC = 0.717, best cut-off value: 21.62) and HOMA-IR could preferably predict FAI (best cut-off value: 2.11, AUC = 0.648).   Our data indicated that the VAI and LAP may contribute to the early identification of IR and hyperandrogenaemia in the obesity/overweight patients of PCOS. In normal weight PCOS, BMI was a better predictor to IR, and HOWA-IR was a better predictor to FAI.",
    "body": "1. Introduction  PCOS is a common reproductive endocrine disease in women of all ages, and the prevalence is approximately 6-10% [ 1 , 2 ]. PCOS is also characterized by central obesity, atherosclerotic dyslipidaemia, IR, hypertension, and reduced high-density lipoprotein cholesterol (HDL-C), so it has been considered a metabolic syndrome (MS), which increases the risk of developing type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CAD) in the future [ 3 ]. Since IR and hyperandrogenaemia are the most important features of PCOS and they also indicate metabolic disorders, early identification of IR and hyperandrogenaemia is of great significance for the prevention of the more serious conditions related to metabolic dysfunction and cardiovascular disease in these women.  Central obesity, also known as visceral obesity, refers to fat hidden between the internal organs of the abdomen. Body fat is the key to assessing obesity, not body weight. Visceral obesity leads to enhanced production of adipocytokines, worsening of inflammatory activity, and insulin sensitivity [ 4 , 5 ]. It has been found that metabolic and endocrine abnormalities that are caused by visceral obesity are the core of PCOS [ 6 ]. Visceral obesity leads to IR and promotes the development of hyperandrogenaemia through IR.  Visceral obesity is usually quantified by computerized tomography (CT) or magnetic resonance imaging (MRI) [ 7 ]. To avoid the high costs and electromagnetic exposure, BMI, WC, WHtR, and WHR are used to evaluate visceral obesity more easily [ 8 , 9 ]. In recent years, indicators combining anthropometric parameters and blood lipid values, such as the VAI and LAP, have shown higher precision in identifying visceral obesity [ 10 ]. Some studies have indicated that the VAI and LAP could calculate MS, IR, T2DM, and CVD in patients with PCOS [ 11 , 12 ]. And the VAI and LAP could predict IR and MS more effectively [ 13 ].  Since adipose tissue has a significant impact on the pathological process of PCOS, there may be different proportions of fat content between obese/overweight and normal weight patients, resulting in different metabolic characteristics. But the study on the predictive value of visceral fat distribution in IR and hyperandrogenaemia in obese and nonobese PCOS women in Northwest China has not been reported. Since ethnic differences and eating habits should also be considered as causes of the differences in the metabolic spectrum [ 14 ], it should have great significance to study the influence of obesity on metabolic and endocrine phenotypes of PCOS in different regions. This study will explore whether the VAI, LAP, or other endocrine or metabolic indicators can predict IR and hyperandrogenaemia in patients with PCOS in Northwest China.  Here, we divided patients with PCOS into two groups, the normal weight group and the obesity/overweight group, according to BMI. Each group was further divided into two subgroups according to their HOMA-IR and FAI. Furthermore, we compared the clinical indices, hormone levels, and metabolic makers separately between these groups and tested the correlations between these parameters and HOMA-IR or FAI. And receiver-operating characteristic (ROC) curves were calculated, and the optimum values of sensitivity and specificity were determined to maintain the predictors of IR and hyperandrogenaemia in patients with PCOS.    2. Methods   2.1. Study Population  This retrospective study involving 953 patients was a cross-sectional study of PCOS. All patients were selected from the reproductive department of the First Affiliated Hospital of Xi'an Jiaotong University from January 2011 to December 2019. PCOS was diagnosed according to the Rotterdam standard [ 15 ]. The participants were 19 years old at the minimum and 40 years old at the maximum. Any patients with thyroid dysfunction, Cushing's syndrome, androgen-secreting tumors, congenital adrenal hyperplasia, and hyperprolactinemia were excluded. None of the patients took any drugs affecting metabolism in the past 3 months. This study was performed in line with the principles of the Declaration of Helsinki (as revised in 2013). Approval was granted by the Ethics Committee of the First Affiliated Hospital of Xi'an Jiaotong University.    2.2. Study Protocol  Two experienced investigators verified height, WC, and hip circumference of the patients. Weight was measured without shoes and coats. The hips were measured from the trochanter major. At the end of exhalation, the waist circumferences were recorded in midpoint between the rib edge and the crest top. BMI was collected through dividing weight by the square of height. According to the definition of China Obesity Working Meta-analysis Group, 24 \u2264 BMI < 28 is defined overweight, and BMI \u2265 28 is defined obesity [ 16 ]. The WHR was obtained through dividing the waist by the hip. The WHtR was obtained through dividing the waist by the height. All patients were grouped to the BMI status. BMI \u2265 24 was the obesity/overweight group, and BMI < 24 was the normal weight group.  Fasting blood collection of the elbow veins was at 8\u2009AM on the 3rd\u20135th days in the natural menstrual period or progestin-withdrawal bleeding of amenorrhoeic participants. The serum levels of low-density lipoprotein cholesterol (LDL-C), total cholesterol (CHO), HDL-C, triglycerides (TGs), lipoprotein (a) (LP (a)), follicle-stimulating hormone (FSH), serum estradiol (E2), testosterone (T), progesterone (P), sex hormone-binding globulin (SHBG), luteinizing hormone (LH), glucose, including fasting glucose (FGS) and 2-hour postprandial blood glucose (F2h), and insulin, including fasting insulin (FIN) and 2-hour postprandial blood insulin (FI2h) were obtained by the electrochemiluminescence immunoassay method (Roche Diagnostics GmbH, Mannheim, Germany). The intra-assay and interassay coefficients of variation (CVs) were <10%.  The free androgen index was obtained using the formula FAI = total\u2009testosterone\u2009(nmol/l)/SHBG\u2009(nmol/l) \u00d7 100. The HOMA-IR index was obtained by the formula HOMA \u2212 IR = insulin\u2009( \u03bc IU/ml) \u00d7 glucose\u2009(mmol/l)/22.5. Insulin resistance was defined as HOMA\u2010IR > 2.77 based on Yen's recommendation [ 17 ]. FAI > 6.10 was considered hyperandrogenaemia. The VAI and LAP index were obtained from the formula [WC(cm)/(36.58 + 1.89 \u00d7 BMI)] \u00d7 TG\u2009(mmol/l)/0.81 \u00d7 1.52/HDL \u2212 C\u2009(mmol/l) and [WC\u2009(cm)\u201358] \u00d7 TG\u2009(mmol/l) [ 18 , 19 ]. PCOS subjects in the obesity/overweight group and the normal weight group were grouped by their HOMA-IR (>2.77 for the IR+ subgroup and \u22642.77 for the IR- subgroup) and FAI values (>6.10 for the FAI+ subgroup and \u22646.10 for the FAI- subgroup).    2.3. Statistical Analysis  Continuous variables were presented as the mean \u00b1 SD. The Kolmogorov\u2013Smirnov test calculated the normality of the distribution. The differences were compared by Student's t test. The correlation between the visceral fat characteristic makers and HOMA-IR and FAI was tested by Spearman correlation analysis. The ROC curve was generated. The optimum values of sensitivity and specificity were determined to maintain the maximum value of the Youden index. A two-tailed p < 0.05 indicates the significant difference. All data were analyzed with the social science statistical software package (SPSS version 22.0, Chicago, Illinois, USA).     3. Results  Among 953 PCOS patients, 525 patients were of normal weight, and 428 patients were obese/overweight, which had been grouped by their BMI. In Table 1 , the clinical indices, hormone levels, and metabolic makers of PCOS of two groups are shown. All parameters (BMI, WHR, WHtR, SHBG, FGS, and FIN) in the normal weight PCOS group were lower than the obesity/overweight PCOS group. Additionally, TG and HDL-C were worse in the obesity/overweight PCOS group, comparing to the normal weight PCOS group. The LAP and VAI were also higher in the obesity/overweight group, comparing normal weight group. The parameters of E 2 , T, CHO, LDL-C, and LP (a) were of no significant differences between the two groups.  In the normal weight group, 174 patients with PCOS had IR (33.14%). There were 342 PCOS patients with IR (79.90%) in the obesity/overweight group. The parameters (BMI, WHtR, SHBG, FGS, FIN, TG, and HDL-C) in the IR+ subgroup were much higher comparing the IR- subgroup in both the obesity/overweight group and normal weight group. The VAI and LAP were also higher in the IR+ subgroup than in the IR- subgroup ( Table 2 ). HOMA-IR was positively correlated with BMI ( p < 0.001, r = 0.335), WHR ( p < 0.001, r = 0.259), WHtR ( p < 0.001, r = 0.376), FAI ( p < 0.001, r = 0.194), VAI ( p < 0.001, r = 0.228), and LAP index ( p < 0.001, r = 0.204) in the normal weight group. HOMA-IR was significantly related to BMI ( p < 0.001, r = 0.380), WHtR ( p < 0.001, r = 0.395), FAI ( p < 0.001, r = 0.264), VAI ( p < 0.001, r = 0.286), and LAP index ( p < 0.001, r = 0.274) in the obesity/overweight group. It did not have a significant relationship with WHR ( p = 0.225, r = 0.059).  In the normal weight group, there were 35 patients with PCOS with hyperandrogenaemia (6.67%). There were 138 patients with PCOS with hyperandrogenaemia (32.24%) in the obesity/overweight group. The parameters (BMI, WHtR, SHBG, FGS, FIN, and HDL-c) in the FAI+ subgroup were higher than those in the FAI- subgroup in both the normal weight group and obesity/overweight group. The VAI and LAP were also higher in the FAI+ subgroup than in the FAI- subgroup ( Table 3 ). FAI was positively correlated with BMI ( p < 0.001, r = 0.298), WHR ( p < 0.001, r = 0.163), WHtR ( p < 0.001, r = 0.237), HOMA-IR ( p < 0.001, r = 0.194), VAI ( p < 0.001, r = 0.191), and LAP index ( p < 0.001, r = 0.201) in the normal weight group. In the obesity/overweight group, FAI has significant relationship with BMI ( p < 0.001, r = 0.133), WHtR ( p < 0.001, r = 0.130), HOMA-IR ( p < 0.001, r = 0.264), VAI ( p < 0.001, r = 0.134), and LAP index ( p < 0.001, r = 0.168). FAI was not significantly related to WHR ( p = 0.567, r = 0.028).  In the obesity/overweight group, the VAI (best cut-off value: 2.27, area\u2009under\u2009the\u2009curve\u2009(AUC) = 0.699) and LAP (best cut-off value: 45.54, AUC = 0.680) were more sensitive predictors of IR. Additionally, in the obesity/overweight groups, the VAI (best cut-off value: 2.13, AUC = 0.624) and LAP (best cut-off value: 51.18, AUC = 0.582) were more sensitive predictors of FAI (Figures 1 and 2 and Tables 4 and 5 ). In Table 4 , the sensitivity of VAI to discriminate IR in normal weight individuals was 37%. The sensitivity of VAI for detecting IR in normal weight was significantly low, and the sensitivity was the lowest among the anthropometric variables. However, the specificity of VAI to discriminate IR in normal weight individuals was 92%. The specificity of VAI for detecting IR in normal weight was significantly high, and the specificity was the highest among the anthropometric variables. Furthermore, in the normal weight group, BMI was a reliable predictor to HOMA-IR (best cut-off value: 21.62, AUC = 0.717). The sensitivity of BMI to discriminate IR in normal weight individuals was 63%, and the sensitivity was the highest among the anthropometric variables. Table 5 showed that the sensitivity of HOWA-IR to discriminate FAI in normal weight individuals was 80%. The sensitivity of HOWA-IR for detecting FAI in normal weight was significantly high, and the sensitivity was the highest among the anthropometric variables. HOWA-IR was a reliable predictor to FAI (best cut-off value: 2.11, AUC = 0.648) in normal weight group.    4. Discussion  Because insulin has a gonadotropin-enhancing effect, IR might be the key characteristic in the metabolic and reproductive process of PCOS. Insulin not only increases the production of adrenal and ovarian steroids but also increases the release of pituitary LH. IR is also related to hyperandrogenaemia. It is very important to identify IR as early as possible and provide therapy to improve insulin sensitivity in PCOS patients. Common IR predictors, such as BMI, WHR, WC, WHtR, and other traditional parameters, are closely related to IR, metabolic syndrome, and cardiovascular risk [ 9 , 20 , 21 ]. Recently, proposed anthropometric indicators, such as the VAI and LAP, show high precision in identifying visceral obesity [ 22 ]. Studies have also shown they could be reliable predictors to IR, MS, T2DM, and CAD in PCOS [ 13 , 23 \u2013 26 ]. Recent studies have reported the LAP and VAI are more sensitive and reliable than anthropometric parameters in predicting IR because these parameters combine the anatomical basis and pathophysiological changes related to fat accumulation. Compared with Western populations, populations in Asian are inclined to exhibit fat accumulation and IR [ 27 , 28 ]. In Chinese patients, obese PCOS is usually accompanied by IR. In this study, 174 patients in the normal weight group were complicated with IR, accounting for 33.14%. In the obesity/overweight group, IR resistance accounted for 79.90%. This study indicated the visceral obesity index based on different body types to predict IR of polycystic ovary syndrome in Northwest China. The VAI and LAP can evaluate IR in women of obesity/overweight who have PCOS. For normal weight of PCOS, traditional BMI can more effectively predict IR. In previous studies, the BMI had a significant correlation with HOMA-IR, and it was the representative marker to assess IR in overweight/obese group of PCOS (BMI \u2265 24), [ 29 ]. In non-PCOS patients, BMI was also markers of IR in overweight/obese group of patients with obstructive sleep apnea (OSA) [ 30 ]. Another research had found BMI was associated positively with IR, and BMI acted as a mediator connecting discrimination with IR without distinguishing between obese and nonobese people [ 31 ]. Other studies had found that increased BMI in early pregnancy was associated with IR, and BMI was a better predictor of IR compared with WHR [ 32 ], which may be related to the fact that normal weight patients are more sensitive to body weight changes. In our study, BMI was a reliable predictor to HOMA-IR (best cut-off value: 21.62, AUC = 0.717). The sensitivity of BMI to discriminate IR in normal weight individuals was 63% ( Table 4 ), and the sensitivity of BMI was higher comparing with the sensitivities of other anthropometric variables. Because no more evidence has been found yet, this result may be related to the source of the patient population in this study. As it should be, all the results need to be verified by expanding the sample size and conducting multicenter clinical experiments. In particular, regardless of whether PCOS patients are of normal weight or are obesity/overweight, there were no significant differences in some endocrine indices, such as E2 and T. These findings indicate that the endocrine changes of PCOS patients are not only affected by weight or visceral obesity but also have more complex pathophysiological reasons, which need to be further explored.  The clinical phenotypes of polycystic ovary syndrome include reproductive and hormone abnormalities. The main manifestations are irregular menstruation and infertility caused by anovulation, polycystic ovary, and excessive androgen at clinical and laboratory levels, leading to menstrual disorders, hirsutism, and IR. Obesity, especially visceral obesity, worsens the metabolic status and aggravates ovulation dysfunction and hyperandrogenaemia [ 33 ]. In PCOS patients with visceral obesity, androgen production, and metabolic clearance are changed, and SHBG levels are decreased [ 34 ]. Testosterone increases lipolysis and enhances the outflow of free fatty acids and IR. Visceral obesity significantly affects metabolism of androgen and IR [ 35 ]. Our study found that the VAI and LAP scores were more sensitive predictors of IR and FAI of PCOS with obesity/overweight. HOMA-IR could well predict hyperandrogenaemia in patients in the normal weight groups. These findings are theoretically supported by the relationship between visceral obesity, hyperandrogenaemia, and IR [ 36 ]. Interestingly, SHBG alone cannot predict hyperandrogenaemia but also reflects the hyperandrogenism of polycystic ovary syndrome. This condition is not only a change in hormone levels but also related to metabolic disorders. The LAP and VAI are easy to collect in daily diagnosis. It might be a useful supplementary index for the comprehensive evaluation of reproductive and metabolic disorders in obesity/overweight patients with PCOS.  There are some limitations in this study. All participants were recruited from infertility clinics. Thus, these patients with PCOS may have a serious phenotype. In addition, most of the selected people are from Northwest China. Therefore, affected by the food composition with more fat in the diet, the proportions of IR were high in both normal weight and obesity/overweight people. In the future, the selection of more participants in the community should be considered to reduce bias. Moreover, we should provide normal and obesity/overweight control groups in the following researches to better study the effects of endocrine and metabolism on PCOS.    5. Conclusion  Our study indicates PCOS patients in Northwest China with different body status can have corresponding predictors of IR and hyperandrogenaemia. Both the VAI and LAP can well predict IR and hyperandrogenaemia in obesity/overweight PCOS. In normal weight PCOS, BMI was sensitive predictor to IR, and HOWA-IR was sensitive predictor to FAI. Early identification of IR and hyperandrogenaemia in women with PCOS according to a body fat index is of great significance for early prevention and intervention and reducing long-term complications.",
    "tables": [
        {
            "title": "No Title",
            "content": "Variable  PCOS   p     Normal weight ( n = 525)  Obesity/overweight ( n = 428)      Age (y)  27.08 \u00b1 3.32  27.48 \u00b1 3.59  0.076    BMI (kg/m 2 )  21.05 \u00b1 1.67  27.73 \u00b1 3.16  0.0001    WHR  0.84 \u00b1 0.07  0.92 \u00b1 0.37  0.0001    WHtR  47.49 \u00b1 4.45  57.90 \u00b1 5.78  0.0001    E 2 (pmol/l)  158.15 \u00b1 77.81  150.66 \u00b1 77.94  0.140    T (nmol/l)  1.15 \u00b1 0.60  1.21 \u00b1 0.60  0.143    LH/FSH ratio  1.71 \u00b1 1.09  1.33 \u00b1 0.72  0.0001    SHBG (nmoL/l)  56.21 \u00b1 38.07  33.55 \u00b1 28.94  0.0001    FAI  3.00 \u00b1 3.06  5.39 \u00b1 4.23  0.0001    FGS (mmol/l)  5.47 \u00b1 0.84  6.02 \u00b1 1.18  0.0001    F2h (mmol/l)  5.99 \u00b1 1.57  7.45 \u00b1 2.21  0.0001    FIN ( \u03bc IU/ml)  10.29 \u00b1 6.29  18.68 \u00b1 8.99  0.0001    FI2h ( \u03bc IU/ml)  75.66 \u00b1 73.52  133.78 \u00b1 145.50  0.0001    HOMA-IR  2.55 \u00b1 1.73  5.14 \u00b1 2.98  0.0001    CHO (mmol/l)  4.17 \u00b1 0.72  5.37 \u00b1 0.49  0.179    TG (mmol/l)  1.17 \u00b1 0.96  1.84 \u00b1 1.19  0.0001    HDL-C (mmol/l)  1.36 \u00b1 0.29  1.13 \u00b1 0.23  0.0001    LDL-C (mmol/l)  2.69 \u00b1 1.3  2.77 \u00b1 1.82  0.831    LP (a) (mg/l)  145.33 \u00b1 142.28  153.02 \u00b1 177.82  0.459    VAI  1.93 \u00b1 2.39  3.60 \u00b1 3.10  0.0001    LAP  26.72 \u00b1 35.84  70.24 \u00b1 57.38  0.0001"
        },
        {
            "title": "No Title",
            "content": "Variable  Normal weight  Obesity/overweight    IR- ( n = 351)  IR+ ( n = 174)   p   IR- ( n = 84)  IR+ ( n = 342)   p       Age (y)  27.11 \u00b1 3.26  26.74 \u00b1 3.53  0.235  28.45 \u00b1 4.15  27.39 \u00b1 3.45  0.015    BMI (kg/m 2 )  20.63 \u00b1 1.57  21.89 \u00b1 1.53  0.0001  26.42 \u00b1 2.82  28.05 \u00b1 3.16  0.0001    WHR  0.83 \u00b1 0.07  0.86 \u00b1 0.07  0.0001  0.88 \u00b1 0.10  0.93 \u00b1 0.41  0.224    WHtR  46.45 \u00b1 4.03  49.59 \u00b1 4.52  0.0001  55.04 \u00b1 4.54  58.60 \u00b1 5.84  0.0001    E 2 (pmol/l)  164.21 \u00b1 79.14  145.94 \u00b1 73.77  0.011  160.79 \u00b1 80.87  148.19 \u00b1 77.13  0.184    T (nmol/l)  1.17 \u00b1 0.63  1.11 \u00b1 0.53  0.294  1.13 \u00b1 0.59  1.23 \u00b1 0.61  0.158    LH/FSH ratio  1.74 \u00b1 1.15  1.63 \u00b1 0.96  0.270  1.42 \u00b1 0.77  1.31 \u00b1 0.70  0.213    SHBG (nmoL/l)  60.80 \u00b1 38.18  46.94 \u00b1 36.21  0.0001  39.91 \u00b1 26.19  32.00 \u00b1 29.39  0.024    FAI  2.69 \u00b1 70  3.64 \u00b1 3.62  0.001  3.74 \u00b1 2.89  5.80 \u00b1 4.41  0.0001    FGS (mmol/l)  5.24 \u00b1 0.64  5.95 \u00b1 0.99  0.0001  5.27 \u00b1 0.78  6.20 \u00b1 1.19  0.0001    F2h (mmol/l)  5.64 \u00b1 1.17  6.68 \u00b1 2.00  0.0001  6.50 \u00b1 1.62  7.68 \u00b1 2.27  0.0001    FIN ( \u03bc IU/ml)  7.42 \u00b1 2.40  16.09 \u00b1 7.58  0.0001  8.28 \u00b1 2.47  21.22 \u00b1 8.14  0.0001    FI2h ( \u03bc IU/ml)  56.46 \u00b1 46.38  114.38 \u00b1 98.81  0.0001  64.80 \u00b1 37.11  150.68 \u00b1 156.78  0.0001    CHO (mmol/l)  4.14 \u00b1 0.71  4.23 \u00b1 0.72  0.194  4.29 \u00b1 0.79  5.64 \u00b1 2.80  0.588    TG (mmol/l)  0.99 \u00b1 0.53  1.56 \u00b1 1.40  0.0001  1.40 \u00b1 0.77  1.95 \u00b1 1.26  0.0001    HDL-C (mmol/l)  1.39 \u00b1 0.28  1.29 \u00b1 0.32  0.0001  1.25 \u00b1 0.28  1.10 \u00b1 0.21  0.0001    LDL-C (mmol/l)  2.82 \u00b1 8.92  2.44 \u00b1 0.66  0.582  2.59 \u00b1 0.64  2.82 \u00b1 2.00  0.306    LP (a) (mg/l)  143.79 \u00b1 137.80  148.47 \u00b1 151.33  0.724  204.50 \u00b1 239.27  140.42 \u00b1 157.10  0.003    VAI  1.45 \u00b1 1.20  2.90 \u00b1 3.61  0.0001  2.36 \u00b1 1.52  3.90 \u00b1 3.30  0.0001    LAP  20.93 \u00b1 31.73  38.41 \u00b1 40.60  0.0001  53.27 \u00b1 52.23  74.38 \u00b1 57.88  0.002"
        },
        {
            "title": "No Title",
            "content": "Variable  Normal weight  Obesity/overweight    FAI- ( n = 490)  FAI+ ( n = 35)   p   FAI- ( n = 288)  FAI+ ( n = 138)   p       Age (y)  27.09 \u00b1 3.32  25.54 \u00b1 3.47\u00b1  0.008  27.66 \u00b1 3.58  27.47 \u00b1 3.70  0.621    BMI (kg/m 2 )  20.98 \u00b1 1.65  22.03 \u00b1 1.47  0.0001  27.49 \u00b1 3.04  28.23 \u00b1 3.34  0.023    WHR  0.84 \u00b1 0.07  0.87 \u00b1 0.06  0.015  0.93 \u00b1 0.44  0.91 \u00b1 0.10  0.573    WHtR  47.33 \u00b1 4.41  49.80 \u00b1 4.38  0.001  57.43 \u00b1 5.77  58.87 \u00b1 5.71  0.016    E 2 (pmol/l)  157.22 \u00b1 77.69  171.21 \u00b1 79.40  0.304  147.71 \u00b1 80.35  156.74 \u00b1 72.64  0.262    T (nmol/l)  1.10 \u00b1 0.56  1.91 \u00b1 0.64  0.0001  0.97 \u00b1 0.48  1.71 \u00b1 0.52  0.0001    LH/FSH ratio  1.70 \u00b1 1.09  1.85 \u00b1 1.07  0.429  1.30 \u00b1 0.73  1.40 \u00b1 0.67  0.162    SHBG (nmoL/l)  58.84 \u00b1 38.00  19.37 \u00b1 8.67  0.0001  41.04 \u00b1 32.39  18.14 \u00b1 7.15  0.0001    HOMA-IR  2.48 \u00b1 1.61  3.56 \u00b1 2.81  0.0001  4.61 \u00b1 2.68  6.25 \u00b1 3.27  0.0001    FGS (mmol/l)  5.48 \u00b1 0.85  5.42 \u00b1 0.64  0.691  5.91 \u00b1 1.13  6.25 \u00b1 1.25  0.004    F2h (mmol/l)  5.91 \u00b1 1.47  7.03 \u00b1 2.40  0.0001  7.16 \u00b1 2.09  8.04 \u00b1 2.33  0.0001    FIN ( \u03bc IU/ml)  9.97 \u00b1 5.63  14.74 \u00b1 11.41  0.0001  17.10 \u00b1 8.36  21.93 \u00b1 9.40  0.0001    FI2h ( \u03bc IU/ml)  70.83 \u00b1 62.70  143.14 \u00b1 147.35  0.0001  119.92 \u00b1 161.40  162.50 \u00b1 99.70  0.004    CHO (mmol/l)  4.17 \u00b1 0.72  4.14 \u00b1 0.68  0.785  5.85 \u00b1 4.92  4.38 \u00b1 0.86  0.485    TG (mmol/l)  1.14 \u00b1 0.93  1.55 \u00b1 1.16  0.014  1.79 \u00b1 1.27  1.93 \u00b1 1.00  0.260    HDL-C (mmol/l)  1.36 \u00b1 0.29  1.30 \u00b1 0.33  0.249  1.16 \u00b1 0.25  1.07 \u00b1 0.19  0.0001    LDL-C (mmol/l)  2.72 \u00b1 7.55  2.38 \u00b1 0.60  0.791  2.78 \u00b1 2.16  2.74 \u00b1 0.73  0.823    LP (a) (mg/l)  146.00 \u00b1 143.74  135.67 \u00b1 120.51  0.682  160.05 \u00b1 192.52  138.4 \u00b1 142.15  0.240    VAI  1.87 \u00b1 2.34  2.85 \u00b1 2.87  0.018  3.39 \u00b1 3.27  4.04 \u00b1 2.66  0.043    LAP  25.57 \u00b1 35.19  42.91 \u00b1 41.28  0.006  66.07 \u00b1 54.79  78.80 \u00b1 61.69  0.031"
        },
        {
            "title": "No Title",
            "content": "Indexes  Cutoff values  SS (%)  SP (%)  AUC    NWP  OWP  NWP  OWP  NWP  OWP  NWP  OWP      BMI  21.62  27.54  63  48  73  82  0.717  0.680    WHR  0.87  0.96  49  29  72  88  0.638  0.604    WHtR  49.79  59.09  58  43  76  84  0.698  0.676    FAI  3.27  5.76  42  41  75  83  0.597  0.641    VAI  2.49  2.27  37  72  92  63  0.656  0.699    LAP  27.81  45.54  46  67  85  63  0.698  0.680"
        },
        {
            "title": "No Title",
            "content": "Indexes  Cutoff values  SS (%)  SP (%)  AUC    NWP  OWP  NWP  OWP  NWP  OWP  NWP  OWP      BMI  21.43  30.17  77  27  59  85  0.683  0.564    WHR  0.87  0.87  60  79  67  31  0.641  0.523    WHtR  49.70  57.46  57  58  73  54  0.662  0.568    LFR  2.77  1.22  29  55  87  58  0.546  0.560    SHBG  29.58  25.17  6  10  16  35  0.056  0.140    HOWA-IR  2.11  5.4  80  54  49  71  0.648  0.666    VAI  2.10  2.13  43  87  79  38  0.596  0.624    LAP  20.48  51.18  63  64  63  50  0.650  0.582"
        }
    ],
    "images": [
        {
            "caption": "ROC curves for indexes with HOMA-IR in PCOS patients. (a) ROC curves for indexes with HOMA-IR in normal weight PCOS patents. (b) ROC curves for indexes with HOMA-IR in obesity/overweight PCOS patents. HOMA-IR: homeostasis model assessment-insulin resistance. BMI: body mass index; WHR: waist-to-hip ratio; WHtR: waist-to-height ratio; FAI: free androgen index; VAI: visceral adiposity index; LAP: lipid accumulation product."
        },
        {
            "caption": "ROC curves for indexes with FAI in PCOS patients. (a) ROC curves for indexes with FAI in normal weight PCOS patents. (b) ROC curves for indexes with FAI in obesity/overweight PCOS patents. FAI: free androgen index; BMI: body mass index; WHR: waist-to-hip ratio; WHtR: waist-to-height ratio; LFR: luteinizing hormone/follicle-stimulating hormone ratio; SHBG: sex hormone-binding globulin; HOMA-IR: homeostasis model assessment-insulin resistance; VAI: visceral adiposity index; LAP: lipid accumulation product."
        }
    ]
}